Dynamic Technology Lab Private Ltd Raises Stock Position in Insulet Corporation $PODD

Dynamic Technology Lab Private Ltd boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 221.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 7,034 shares of the medical instruments supplier’s stock after purchasing an additional 4,845 shares during the quarter. Insulet makes up 0.5% of Dynamic Technology Lab Private Ltd’s portfolio, making the stock its 21st largest position. Dynamic Technology Lab Private Ltd’s holdings in Insulet were worth $1,999,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of PODD. Glenmede Investment Management LP grew its holdings in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 35 shares during the last quarter. Curi Capital LLC grew its holdings in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the last quarter. WINTON GROUP Ltd grew its holdings in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares during the last quarter. Camarda Financial Advisors LLC grew its holdings in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Great Lakes Advisors LLC grew its holdings in Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PODD. Piper Sandler cut their price target on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Citigroup dropped their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Robert W. Baird dropped their price objective on shares of Insulet from $360.00 to $248.00 in a report on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Finally, Benchmark reissued a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $240.78.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is owned by corporate insiders.

Insulet Price Performance

Shares of PODD opened at $149.70 on Friday. The firm has a market capitalization of $10.37 billion, a PE ratio of 34.81, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88. The company’s fifty day moving average price is $169.92 and its 200-day moving average price is $232.67.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts predict that Insulet Corporation will post 6.46 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.